Harte Hanks (HHS) Cash & Equivalents (2010 - 2026)

Harte Hanks (HHS) has 17 years of Cash & Equivalents data on file, last reported at $4.5 million in Q1 2026.

• Quarterly Cash & Equivalents fell 49.48% year-over-year to $4.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.5 million (down 49.48% YoY) and the FY2025 annual result came in at $5.6 million, down 43.76% from the prior year.
• Cash & Equivalents retreated to $4.5 million in Q1 2026 per HHS's latest filing, from $5.6 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $18.9 million in Q4 2023 and bottomed at $4.5 million in Q1 2026.
• The 5-year median for Cash & Equivalents is $9.9 million (2024), against an average of $9.7 million.
• The widest annual swing landed in 2022, when Cash & Equivalents slumped 63.57%; it then soared 92.38% in 2023.
• Tracing HHS's Cash & Equivalents over 5 years: stood at $10.4 million in 2022, then surged by 82.01% to $18.9 million in 2023, then slumped by 47.34% to $9.9 million in 2024, then tumbled by 43.76% to $5.6 million in 2025, then declined by 18.78% to $4.5 million in 2026.
• Per Business Quant, the three latest HHS Cash & Equivalents figures stand at $4.5 million (Q1 2026), $5.6 million (Q4 2025), and $6.5 million (Q3 2025).

Peer Comparison